RASolute 304 is anticipated to enroll approximately 500 patients with PDAC harboring oncogenic RAS mutations who have undergone resection and completed perioperative chemotherapy. The trial will ...
When it comes to the current state of cancer survival, Susan Bates feels like many of the rest of us. "It's incredibly frustrating," she says. For Bates, who treats pancreatic and other cancers at ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II ...
Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor ...
Pancreatic cancer is extremely aggressive and often has a poor prognosis, so understanding the underlying molecular mechanism that keeps these particular cancer cells alive is critical to improving ...
Protein systems make up the complex signaling pathways that control whether a cell divides or, in some cases, metastasizes. Ras proteins have long been the focus of cancer research because of their ...
RAS genes constitute the most regularly mutated oncogene family in cancer. Indeed, RAS genes constituted the most regularly mutated oncogenes in the top three causes of cancer deaths in the US in 2016 ...
K-Ras mutations are all too familiar as drivers of cancer. And until recently, they were considered all but undruggable. But ever since the arrival of sotorasib and adagrasib—two FDA-approved ...
As a 10-year journey comes to fruition, MUSC Hollings Cancer Center researcher John O’Bryan, Ph.D., and colleagues have demonstrated a new therapeutic way to block a protein that is frequently mutated ...
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit Looks Back at Pancreatic Cancer in 2025: A Year of Progress, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback